ESC 365 - Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control

EAPC Premium Access

Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control

Session: Rapid fire abstracts - Secondary Prevention and Rehabilitation

Topic: Health Economics

Speaker: Mr G. Rubio (Barcelona, ES)

Event: ESC Preventive Cardiology 2021

Congress Presentation

Add to my library

About the speaker

Mr Gabriel Rubio

Ferrer Internacional, Barcelona (Spain)

0 follower

4 more presentations in this session

Cardiac rehabilitation is associated with lower 1-year all-cause mortality in primary pulmonary hypertension

Speaker: Mr G. Kleinnibbelink (Nijmegen, NL)

Associations of severity of liver damages with physical function and prognosis in patients with heart failure

Speaker: Mr T. Noda (Sagamihara, JP)

Association of type 2 diabetes mellitus and mortality after coronary artery bypass graft surgery- a meta analysis

Speaker: Ms A. Abdul Razzack (Vijayawada, IN)

How consistent are cost-effectiveness estimates of a cardiovascular polypill strategy for the secondary prevention of cardiovascular disease across different cardiovascular risk equations?

Speaker: Mr D. Carcedo (Barcelona, ES)

Access the full session

Rapid fire abstracts - Secondary Prevention and Rehabilitation

Speakers: Mr G. Rubio, Mr G. Kleinnibbelink, Mr T. Noda, Ms A. Abdul Razzack, Mr D. Carcedo

About the event

ESC Preventive Cardiology 2021

15 April - 17 April 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources